



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Evatanepag

<b>Cat. No.:</b>	HY-14839		
<b>CAS No.:</b>	223488-57-1		
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>28</sub> N <sub>2</sub> O <sub>5</sub> S		
<b>Molecular Weight:</b>	468.57		
<b>Target:</b>	Prostaglandin Receptor		
<b>Pathway:</b>	GPCR/G Protein		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 32 mg/mL (68.29 mM)  
 \* "≥" means soluble, but saturation unknown.

Concentration	Mass		
	1 mg	5 mg	10 mg
<b>1 mM</b>	2.1342 mL	10.6708 mL	21.3415 mL
<b>5 mM</b>	0.4268 mL	2.1342 mL	4.2683 mL
<b>10 mM</b>	0.2134 mL	1.0671 mL	2.1342 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Evatanepag (CP-533536) is a non-prostanoid, potent and selective EP<sub>2</sub> receptor agonist. Evatanepag can induce local bone formation in vivo. Evatanepag can be used in the research of fractures, bone defects, asthma<sup>[1][2]</sup>.

#### IC<sub>50</sub> & Target

EP<sub>2</sub>

#### In Vitro

Evatanepag (10 nM, 30 min) inhibits hFcεRI-induced mast cells degranulation in a dose-dependent manner<sup>[2]</sup>.  
 Evatanepag (0.1 nM-10 μM, 12 min) results in an equivalent increase in intracellular cAMP in HEK-293 cells, with an IC<sub>50</sub> of 50 nM<sup>[3]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Evatanepag (0.3-3.0 mg/kg, directly injected into the marrow cavity of the tibia) promotes bone formation in rats<sup>[1]</sup>.  
 Evatanepag (0.3, 3.0 mg/kg, intranasal administration, from day1 to day4) reduces HDM aeroallergen-induced increased RL response to methacholine in mice<sup>[2]</sup>.  
 Evatanepag (1 mg/kg, intravenous injection) demonstrates high i.v. clearance (Cl: 56 mL/min/kg) and a short half-life (t<sub>1/2</sub>:

0.33 h)<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rats <sup>[1]</sup>
Dosage:	0.3, 1.0, 3.0 mg/kg
Administration:	Directly injected into the marrow cavity of the tibia
Result:	Dose-dependently increased in bone area, bone mineral content, bone mineral density.

Animal Model:	HDM (house dust mite)-sensitized BALB/c mice <sup>[2]</sup>
Dosage:	0.3 mg/kg, 3 mg/kg
Administration:	Intranasal administration, from day1 to day4
Result:	Prevented aeroallergen-driven increased RL (lung resistance) at 0.3 mg/kg. Prevented the enhanced MC activity by approximately 48% at 3 mg/kg.

## CUSTOMER VALIDATION

- Sci Adv. 2021 Apr 2;7(14):eabf1268.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Judith Plaza, et al. In Vitro and In Vivo Validation of EP2-Receptor Agonism to Selectively Achieve Inhibition of Mast Cell Activity. Allergy Asthma Immunol Res. 2020 Jul;12(4):712-728.
- [2]. V M Paralkar, et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6736-40.
- [3]. Cameron KO, et al. Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2075-8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA